Literature DB >> 24078057

Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients.

Marta Toni, José Hermida, María J Goñi, Patricia Fernández, William C Parks, Estefanía Toledo, Ramón Montes, Nieves Díez.   

Abstract

AIMS/HYPOTHESIS: The role of metalloproteinase-10 (MMP-10) in type 1 diabetes is not known. We hypothesise that it plays a role in the onset and progression of diabetic nephropathy and retinopathy.
METHODS: Serum MMP-10 levels from 269 patients with type 1 diabetes were measured, and their association with microvascular complications was analysed. We also studied whether knocking out the Mmp10 gene influenced the extent of renal injury and retinal damage in a streptozotocin-induced diabetic mouse model.
RESULTS: The risk of nephropathy and proliferative retinopathy associated with the highest vs the lowest MMP-10 tertile was increased three to four times independently of the classical risk factors. Accordingly, renal function and morphology were better preserved in diabetic Mmp10 −⁄− mice than in their Mmp10 +/+ counterparts. There were more kidney-infiltrating macrophages in diabetic Mmp10+/+ mice, suggesting that MMP-10 contributes to the inflammatory response leading to microvascular complications. The loss of neuronal cells in the retinas of diabetic Mmp10 +/+ mice was higher than in Mmp10 −⁄− mice. Retinal inflammation was decreased in Mmp10 −⁄− mice, as indicated by their reduced retinal caspase-1 levels. CONCLUSIONS/
INTERPRETATION: MMP-10 is involved in the development of microvascular complications in type 1 diabetes and emerges as a potential therapeutic target for slowing down the evolution of diabetic nephropathy and retinopathy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24078057     DOI: 10.1007/s00125-013-3052-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  50 in total

1.  Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes.

Authors:  Ian B McKittrick; Yolanda Bogaert; Kristen Nadeau; Janet Snell-Bergeon; Amber Hull; Tao Jiang; Xiaoxin Wang; Moshe Levi; Karen S Moulton
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

2.  Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy.

Authors:  Carin Gustavsson; Carl-David Agardh; Elisabet Agardh
Journal:  Acta Ophthalmol       Date:  2012-04-20       Impact factor: 3.761

3.  Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients.

Authors:  Pedro Romero; Mercè Salvat; Juan Fernández; Marc Baget; Inmaculada Martinez
Journal:  J Diabetes Complications       Date:  2007 Mar-Apr       Impact factor: 2.852

4.  C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis.

Authors:  Ines Montero; Josune Orbe; Nerea Varo; Oscar Beloqui; José I Monreal; José A Rodríguez; Javier Díez; Peter Libby; José A Páramo
Journal:  J Am Coll Cardiol       Date:  2006-03-20       Impact factor: 24.094

Review 5.  Retinal ganglion cells in diabetes.

Authors:  Timothy S Kern; Alistair J Barber
Journal:  J Physiol       Date:  2008-06-19       Impact factor: 5.182

6.  Non-uniform distribution of lesions and biochemical abnormalities within the retina of diabetic humans.

Authors:  J Tang; S Mohr; Y-D Du; T S Kern
Journal:  Curr Eye Res       Date:  2003-07       Impact factor: 2.424

7.  Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis.

Authors:  Henrik Toft-Hansen; Robert K Nuttall; Dylan R Edwards; Trevor Owens
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

8.  Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values.

Authors:  Laura Mäkitalo; Taina Sipponen; Päivi Kärkkäinen; Kaija-Leena Kolho; Ulpu Saarialho-Kere
Journal:  Int J Colorectal Dis       Date:  2009-08-04       Impact factor: 2.571

9.  Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion.

Authors:  Carin Gustavsson; Carl-David Agardh; Per Hagert; Elisabet Agardh
Journal:  Retina       Date:  2008-04       Impact factor: 4.256

10.  Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage.

Authors:  Renu A Kowluru; Ghulam Mohammad; Julia M dos Santos; Qing Zhong
Journal:  Diabetes       Date:  2011-09-20       Impact factor: 9.461

View more
  16 in total

1.  Matrix metalloproteinase-10 and microvascular complications of type 1 diabetes: might vitamin D status be relevant?

Authors:  Barbara J Boucher
Journal:  Diabetologia       Date:  2014-02-16       Impact factor: 10.122

2.  MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes.

Authors:  Manuel Navarro-Oviedo; Carmen Roncal; Agustina Salicio; Miriam Belzunce; Obdulia Rabal; Estefanía Toledo; Beatriz Zandio; Jose A Rodríguez; Jose A Páramo; Roberto Muñoz; Josune Orbe
Journal:  Transl Stroke Res       Date:  2018-07-27       Impact factor: 6.829

3.  Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.

Authors:  Mai Sugahara; Shinji Tanaka; Tetsuhiro Tanaka; Hisako Saito; Yu Ishimoto; Takeshi Wakashima; Masatoshi Ueda; Kenji Fukui; Akira Shimizu; Reiko Inagi; Toshimasa Yamauchi; Takashi Kadowaki; Masaomi Nangaku
Journal:  J Am Soc Nephrol       Date:  2020-01-29       Impact factor: 10.121

Review 4.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

5.  Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study.

Authors:  Stijn A Peeters; Lian Engelen; Jacqueline Buijs; Nish Chaturvedi; John H Fuller; Casper G Schalkwijk; Coen D Stehouwer
Journal:  Cardiovasc Diabetol       Date:  2015-03-10       Impact factor: 9.951

6.  Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.

Authors:  S A Peeters; L Engelen; J Buijs; A Jorsal; H-H Parving; L Tarnow; P Rossing; C G Schalkwijk; C D A Stehouwer
Journal:  Cardiovasc Diabetol       Date:  2017-04-26       Impact factor: 9.951

Review 7.  Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD).

Authors:  Luis García-Onrubia; Fco Javier Valentín-Bravo; Rosa M Coco-Martin; Rogelio González-Sarmiento; J Carlos Pastor; Ricardo Usategui-Martín; Salvador Pastor-Idoate
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

8.  Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach.

Authors:  Axel C Carlsson; Christoph Nowak; Lars Lind; Carl Johan Östgren; Fredrik H Nyström; Johan Sundström; Juan Jesus Carrero; Ulf Riserus; Erik Ingelsson; Tove Fall; Johan Ärnlöv
Journal:  Ups J Med Sci       Date:  2019-12-05       Impact factor: 2.384

9.  Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients.

Authors:  Jin-Woo Kwon; Jin A Choi; Donghyun Jee
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage.

Authors:  Manuel Navarro-Oviedo; Roberto Muñoz-Arrondo; Beatriz Zandio; Juan Marta-Enguita; Anna Bonaterra-Pastra; Jose Antonio Rodríguez; Carmen Roncal; Jose A Páramo; Estefania Toledo; Joan Montaner; Mar Hernández-Guillamon; Josune Orbe
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.